Here are relevant reports on : osteoarthritis-therapeutics-market
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
-
Medical Automation Market by Application (Diagnostics & Monitoring, Therapeutics, Lab & Pharmacy Automation, Medical Logistics & Training), End-User (Hospital, Diagnostic Center, Research Institute, Home/Ambulatory Care) - Global Forecast to 2020
The global medical automation market over the forecast period of 2015 to 2020. The market is expected to reach USD 55.03 Billion by 2020, at CAGR of 9.5% from 2015 to 2020. Continuous technological advancements in automation solutions, increasing government financial support for medical automation, rising labour costs, and growing need for reproducibility and accuracy are key factors fuelling the growth of the medical automation market. Increasing demand for automation in laboratories and pharmacies and high potential for early detection and treatment of diseases due to automation are some other prime factors offering growth opportunities for players in the medical automation market. However, high cost of automation is one of the key restraints for this market.
- Published: February 2016
- Price: $ 4950
- TOC Available:
-
Digital Therapeutics Market / DTx Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028
The global digital therapeutics market, valued at US$4.4 billion in 2022, stood at US$6.1 billion in 2023 and is projected to advance at a resilient CAGR of 29.1% from 2023 to 2028, culminating in a forecasted valuation of US$21.9 billion by the end of the period. The rapid adoption of digital therapeutics is driven by the rising incidence of chronic diseases, surging investments from venture capital firms, and strategic partnerships between tech companies and healthcare providers.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application [Diagnostics (Clinical, PoC), Research (Proteomics, Genomics, Cell), Therapeutics (Drug Delivery Wearables)], End User – Global forecast to 2030
The global Microfluidics market, valued at US$23.71 billion in 2024, stood at US$24.96 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2030, culminating in a forecasted valuation of US$37.19 billion by the end of the period. Several significant factors are driving the growth of the microfluidics market, thereby enhancing its expansion and applications. There is a growing demand for point-of-care diagnostics, which require fast, accurate, and cost-effective instruments.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
US Medical Gas and Equipment Market by Type [Medical Gas (Oxygen, Nitrous Oxide), Medical Gas Equipment (Flowmeter, Others)], Application [Therapeutics, Diagnostics], End User [Hospital, Home Healthcare] Forecast to 2031
The US Medical Gas and Equipment Market, valued at USD 8.18 million in 2024, stood at USD 8.63 million in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2031, culminating in a forecasted valuation of USD 11.97 million by the end of the period. The growth of the medical gas and equipment market in US is primarily driven by the rising incidence of respiratory and chronic diseases, including COPD, asthma, cardiovascular disorders, and sleep apnea, as well as a rapidly aging population that requires long-term oxygen therapy and critical care support.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
